The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Impact of dabigatran on a large panel of routine or specific coagulation assays: Laboratory recommendations for monitoring of dabigatran etexilate
Abstract
Summary: Due to low bioavailability and high inter-individual variability, monitoring of dabigatran may be required in specific situations to prevent the risk of bleedings or thrombosis. The aim of the study was to determine which coagulation assay(s) could be used to assess the impact of dabig-atran on secondary haemostasis. Dabigatran was spiked at concentrations ranging from 4.7 ng/ml to 943.0 ng/ml in pooled citrated human platelet-poor plasma. The following clotting assays were performed: prothrombin time (PT); activated partial thromboplastin time (aPTT); thrombin time (TT); ecarin clotting time (ECT); ecarin chromo-genic assay (ECA); prothrombinase-induced clotting time (PiCT); activated clotting time (ACT); Hemoclot Thrombin Inhibitor (HTI) and thrombin generation assay (TGA). A concentration-dependent prolongation of PT, dPT, and aPTT was observed with aPTT being the more sensitive test. The results varied mostly due to the clotting reagent. HTI, ECT and TGA were the most sensitive tests but are not available 24 hours a day. In addition, HTI showed a linear correlation with a good reproduci-bility. Dabigatran induced a concentration-dependent delay and inhibition of tissue factor-induced TGA. Cut-offs related with higher risk of bleedings or thrombosis were defined for each reagent of aPTT and HTI. In conclusion, aPTT could be used for the monitoring of dabigatran and as screening test for the risk of overdose. However, because of its higher sensitivity, good reproducibility, excellent linear correlation at all doses, its simplicity of use, and possibilities of automation, HTI should be considered as the gold-standard.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Calibrated Automated Thrombin Generation Measurement in Clotting Plasma
Hemker, H. C., Giesen, P., Al Dieri, R., Regnault, V., de Smedt, E., Wagenvoord, R., Lecompte, T., & Béguin, S. (2003) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000071636 · Cited by 1,430
Stangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M., Clemens, A., & Ryn, J. V. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0758 · Cited by 1,382
Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C., Buller, H. R., & Levi, M. (2011) · Circulation · doi:10.1161/circulationaha.111.029017 · Cited by 1,361
Stangier, J., Rathgen, K., Stähle, H., Gansser, D., & Roth, W. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02899.x · Cited by 887
Newly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Stangier, J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00001 · Cited by 655
Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
Martinoli, J.-L., LeFlem, L., Guinet, C., Plu-Bureau, G., Depasse, F., Perzborn, E., & Samama, M. M. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0176 · Cited by 449
Cited by
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,899
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2015) · Europace · doi:10.1093/europace/euv309 · Cited by 1,113
Horlocker, T. T., Vandermeuelen, E., Kopp, S. L., Gogarten, W., Leffert, L. R., & Benzon, H. T. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000763 · Cited by 932
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2013) · Europace · doi:10.1093/europace/eut083 · Cited by 792
Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants
Cuker, A., Siegal, D. M., Crowther, M. A., & Garcia, D. A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.065 · Cited by 449
Gosselin, R., Adcock, D., Bates, S., Douxfils, J., Favaloro, E., Gouin-Thibault, I., Guillermo, C., Kawai, Y., Lindhoff-Last, E., & Kitchen, S. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1627480 · Cited by 392
Self-citationHow I treat anticoagulated patients undergoing an elective procedure or surgery
Spyropoulos, A. C., & Douketis, J. D. (2012) · Blood · doi:10.1182/blood-2012-06-415943 · Cited by 375
Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants
Samuelson, B. T., Cuker, A., Siegal, D. M., Crowther, M., & Garcia, D. A. (2017) · Chest · doi:10.1016/j.chest.2016.08.1462 · Cited by 345
Pernod, G., Albaladejo, P., Godier, A., Samama, C. M., Susen, S., Gruel, Y., Blais, N., Fontana, P., Cohen, A., Llau, J. V., et al. (2013) · Archives of Cardiovascular Diseases · doi:10.1016/j.acvd.2013.04.009 · Cited by 309
Martinuzzo, M. E., Barrera, L. H., D 'Adamo, M. A., Otaso, J. C., Gimenez, M. I., & Oyhamburu, J. (2014) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12138 · Cited by 91
“extensive paper published recently [5, 6].”
Favresse, J., Lardinois, B., Sabor, L., Devalet, B., Vandepapeliere, J., Braibant, M., Lessire, S., Chatelain, B., Jacqmin, H., Douxfils, J., et al. (2018) · TH Open · doi:10.1055/s-0038-1657785 · Cited by 73
Self-citationEffects of Direct Oral Anticoagulants on Lupus Anticoagulant Assays in a Real-Life Setting
Antovic, A., Norberg, E.-M., Berndtsson, M., Rasmuson, A., Malmström, R. E., Skeppholm, M., & Antovic, J. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-03-0204 · Cited by 46
Evaluation of DOAC Filter, a New Device to Remove Direct Oral Anticoagulants from Plasma Samples
Sevenet, P., Cucini, V., Hervé, T., Depasse, F., Carlo, A., Contant, G., & Mathieu, O. (2020) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13267 · Cited by 21
Metadata
- Authors
- Robert, S., Chatelain, C., Douxfils, J., Mullier, F., Chatelain, B., & Dogné, J.-M.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2012
- Volume
- 107
- Issue
- 05
- Pages
- 985-997
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2156970332
- Cited by
- 325
- References
- 28
- FWCI
- 34.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.